Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Bauer, K. A.    Related Articles in PubMed    PubMed Citation    PubMed

PERSPECTIVE

The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications

Kenneth A. Bauer, MD

4 September 2001 | Volume 135 Issue 5 | Pages 367-373

Discovery of the factor V Leiden and prothrombin G20210A mutations has greatly increased the percentage of patients in whom venous thrombosis can be attributed to hereditary thrombophilia. The first step in the diagnostic approach to all patients with venous thrombosis consists of a careful history and physical examination combined with routine laboratory testing to characterize the severity of the thrombotic condition and determine the presence of any of the acquired causes of hypercoagulability. The second step is to consider screening for the causes of hereditary and acquired thrombophilia in selected subsets of patients. The selection of patients for testing, the choice of tests to perform, and the timing of the testing are important and challenging issues to consider.

Routine testing would be warranted if the identification of abnormalities led to an alteration in the type or duration of initial anticoagulant therapy or the use of long-term prophylactic anticoagulation. The available data, however, do not yet indicate that most patients with defined thrombophilic states should be managed any differently than patients without identifiable abnormalities. On the basis of relative prevalences of the various thrombophilias, patients can be classified as "strongly" or "weakly" thrombophilic depending on their thrombotic histories. Management considerations and guidelines are offered for patients who are found to have one or more defined abnormalities, hereditary or otherwise. The future identification of additional laboratory abnormalities predisposing patients to thrombosis, coupled with prospective clinical trials, should enable us to better identify patients at high risk for recurrence who will benefit from prolonged anticoagulant prophylaxis.

Author and Article Information

From Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts.

Grant Support: In part by the Medical Research Service of the U.S. Department of Veterans Affairs.

Requests for Single Reprints: Kenneth A. Bauer, MD, Veterans Affairs Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132; e-mail, kbauer{at}caregroup.harvard.edu.

This article has been cited by other articles:

				A. Marchiori, L. Mosena, M. H. Prins, and P. Prandoni The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies Haematologica, August 1, 2007; 92(8): 1107 - 1114. [Abstract] [Full Text] [PDF]

				P. S. Wells, J. L. Anderson, D. K. Scarvelis, S. P. Doucette, and F. Gagnon Factor XIII Val34Leu Variant Is Protective against Venous Thromboembolism: A HuGE Review and Meta-Analysis Am. J. Epidemiol., July 15, 2006; 164(2): 101 - 109. [Abstract] [Full Text] [PDF]

				I Richard The genetic and molecular bases of monogenic disorders affecting proteolytic systems J. Med. Genet., July 1, 2005; 42(7): 529 - 539. [Abstract] [Full Text] [PDF]

				T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]

				A. Tripodi, V. Chantarangkul, I. Martinelli, P. Bucciarelli, and P. M. Mannucci A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism Blood, December 1, 2004; 104(12): 3631 - 3634. [Abstract] [Full Text] [PDF]

				S. Bortolin, M. Black, H. Modi, I. Boszko, D. Kobler, D. Fieldhouse, E. Lopes, J.-M. Lacroix, R. Grimwood, P. Wells, et al. Analytical Validation of the Tag-It High-Throughput Microsphere-Based Universal Array Genotyping Platform: Application to the Multiplex Detection of a Panel of Thrombophilia-Associated Single-Nucleotide Polymorphisms Clin. Chem., November 1, 2004; 50(11): 2028 - 2036. [Abstract] [Full Text] [PDF]

				A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]

				B. S. Donahue Factor V Leiden and Perioperative Risk Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634. [Abstract] [Full Text] [PDF]

				L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]

				S. Eichinger, E. Minar, C. Bialonczyk, M. Hirschl, P. Quehenberger, B. Schneider, A. Weltermann, O. Wagner, and P. A. Kyrle D-Dimer Levels and Risk of Recurrent Venous Thromboembolism JAMA, August 27, 2003; 290(8): 1071 - 1074. [Abstract] [Full Text] [PDF]

				G. Palareti, C. Legnani, B. Cosmi, L. Valdre, B. Lunghi, F. Bernardi, and S. Coccheri Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Circulation, July 22, 2003; 108(3): 313 - 318. [Abstract] [Full Text] [PDF]

				P. Prandoni, F. Bilora, A. Marchiori, E. Bernardi, F. Petrobelli, A. W.A. Lensing, M. H. Prins, and A. Girolami An Association between Atherosclerosis and Venous Thrombosis N. Engl. J. Med., April 10, 2003; 348(15): 1435 - 1441. [Abstract] [Full Text] [PDF]

				M. H. Eckman, J. K. Erban, S. K. Singh, and G. S. Kao Screening for the Risk for Bleeding or Thrombosis Ann Intern Med, February 4, 2003; 138(3): W-15 - W-24. [Abstract] [Full Text] [PDF]

				S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]

				W. Burke Genetic Testing N. Engl. J. Med., December 5, 2002; 347(23): 1867 - 1875. [Full Text] [PDF]

				C. E. Ettingshausen, K. Kurnik, R. Schobess, W. D. Kreuz, S. Halimeh, H. Pollman, U. Nowak-Gottl ;, J. M. Journeycake, and G. R. Buchanan Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease Blood, February 15, 2002; 99(4): 1499 - 1499. [Full Text] [PDF]

				K. A. Bauer, F. R. Rosendaal, and J. A. Heit Hypercoagulability: Too Many Tests, Too Much Conflicting Data Hematology, January 1, 2002; 2002(1): 353 - 368. [Abstract] [Full Text]